Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024

Background/Objectives: Long-acting insulin glargine (iGlar) has been available as a biosimilar since 2014 in the UK. We reviewed previous prescribing to evaluate if the anticipated cost savings with biosimilars were realized with iGlar. Methods: This study investigated prescribing patterns of long-a...

Full description

Saved in:
Bibliographic Details
Main Authors: Murtada Alsaif, Zoë Blumer
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Pharmacy
Subjects:
Online Access:https://www.mdpi.com/2226-4787/13/3/85
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849431761331683328
author Murtada Alsaif
Zoë Blumer
author_facet Murtada Alsaif
Zoë Blumer
author_sort Murtada Alsaif
collection DOAJ
description Background/Objectives: Long-acting insulin glargine (iGlar) has been available as a biosimilar since 2014 in the UK. We reviewed previous prescribing to evaluate if the anticipated cost savings with biosimilars were realized with iGlar. Methods: This study investigated prescribing patterns of long-acting iGlar (100 units/mL) in cartridges and pre-filled pens from 2020 to 2024 across primary care organizations in England, Northern Ireland, Scotland, and Wales. Results: iGlar prescribing declined in all of the four nations. From 2020 to 2024, the total prescribed quantity of biosimilars persistently increased in all countries, reaching 24% in England, 5% in Northern Ireland, 24% in Scotland, and 11% in Wales, all in 2024. Consequently, the proportion of Lantus prescriptions (as quantity) decreased but continued to exceed that of all available iGlar products combined in all countries in all years analyzed. By 2024, Lantus was also priced lower than the most common biosimilar, Abasaglar, across all nations. Conclusions: The introduction of biosimilars does not automatically result in altered prescribing practices, though we show that the most commonly prescribed iGlar was also the least expensive product at the end of the analysis period. At launch and for several years after, biosimilars failed to gain strong utilization, despite cost advantages, highlighting the need for active switching policies and prescriber engagement.
format Article
id doaj-art-54982c832db64116ba0d0d7dfa128512
institution Kabale University
issn 2226-4787
language English
publishDate 2025-06-01
publisher MDPI AG
record_format Article
series Pharmacy
spelling doaj-art-54982c832db64116ba0d0d7dfa1285122025-08-20T03:27:32ZengMDPI AGPharmacy2226-47872025-06-011338510.3390/pharmacy13030085Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024Murtada Alsaif0Zoë Blumer1PharmaSaif Ltd., Slough SL2 2LR, UKZoe Blumer Consulting Ltd., Bognor Regis PO21 3TL, UKBackground/Objectives: Long-acting insulin glargine (iGlar) has been available as a biosimilar since 2014 in the UK. We reviewed previous prescribing to evaluate if the anticipated cost savings with biosimilars were realized with iGlar. Methods: This study investigated prescribing patterns of long-acting iGlar (100 units/mL) in cartridges and pre-filled pens from 2020 to 2024 across primary care organizations in England, Northern Ireland, Scotland, and Wales. Results: iGlar prescribing declined in all of the four nations. From 2020 to 2024, the total prescribed quantity of biosimilars persistently increased in all countries, reaching 24% in England, 5% in Northern Ireland, 24% in Scotland, and 11% in Wales, all in 2024. Consequently, the proportion of Lantus prescriptions (as quantity) decreased but continued to exceed that of all available iGlar products combined in all countries in all years analyzed. By 2024, Lantus was also priced lower than the most common biosimilar, Abasaglar, across all nations. Conclusions: The introduction of biosimilars does not automatically result in altered prescribing practices, though we show that the most commonly prescribed iGlar was also the least expensive product at the end of the analysis period. At launch and for several years after, biosimilars failed to gain strong utilization, despite cost advantages, highlighting the need for active switching policies and prescriber engagement.https://www.mdpi.com/2226-4787/13/3/85insulininsulin glarginebiosimilarprimary careprescribing datareal-world data
spellingShingle Murtada Alsaif
Zoë Blumer
Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
Pharmacy
insulin
insulin glargine
biosimilar
primary care
prescribing data
real-world data
title Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
title_full Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
title_fullStr Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
title_full_unstemmed Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
title_short Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom’s Primary Care from 2020 to 2024
title_sort insulin glargine biosimilar prescribing and cost trends in the united kingdom s primary care from 2020 to 2024
topic insulin
insulin glargine
biosimilar
primary care
prescribing data
real-world data
url https://www.mdpi.com/2226-4787/13/3/85
work_keys_str_mv AT murtadaalsaif insulinglarginebiosimilarprescribingandcosttrendsintheunitedkingdomsprimarycarefrom2020to2024
AT zoeblumer insulinglarginebiosimilarprescribingandcosttrendsintheunitedkingdomsprimarycarefrom2020to2024